Cambridge Healthtech Institute’s Seventh Annual

Personalized Diagnostics

Establishing Clinical Sequencing as a Routine Diagnostic Tool

March 7 – 9, 2016 | Moscone North Convention Center | San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference

 

This year, we will investigate subjects of controversy in the implementation of next-generation sequencing for routine clinical use. This includes deciphering driver mutations, determining when to sequence tumor DNA, using matched controls, evaluating and validating exome sequencing for routine diagnosis, profiling DNA to overcome tumor resistance and heterogeneity, weighing uses of tissue biopsy vs. cell-free DNA, and factoring in cost. The Personalized Diagnostics conference promises to be a dynamic interchange of ideas and advances impacting the field.

Preliminary Agenda


PANEL DISCUSSION: NGS REGULATORY OVERSIGHT AND STANDARDS

“So You’ve Sequenced My Genome. How Well Did You Do?” - Resources for Validating Clinical Next-Gen Sequencing

Marc Salit, Ph.D., Leader, Genome-Scale Measurements Group, NIST Material Measurement Lab, NIST-JIMB; Consulting Professor, Department of Bioengineering, Stanford University

Regulatory Considerations for Next-Generation Sequencing

Xueying Sharon Liang, M.D., Ph.D., Regulatory Scientist, Division of Molecular Genetics and Pathology, OIR/CDRH, FDA


PANEL DISCUSSION: WHOLE EXOME SEQUENCING AS A DIAGNOSTIC TOOL

Clinical Exome Sequencing: Utilities and Obstacles to Implementation in a Clinical Setting

Yaping Yang, Ph.D., Associate Professor, Molecular and Human Genetics, Baylor College of Medicine

The Future Use of Exome Sequencing as the Genetic Test of Choice for Clinical Diagnostics

Wendy Chung, M.D., Associate Professor, Clinical Genetics Program, Columbia University

SNP-Catcher, a Database to Aid Mutation Detection and Discovery in Constitutional Disorders and Cancer

Peter L. Nagy, M.D., Ph.D., Assistant Professor, Pathology and Cell Biology; Director, Clinical Next Generation Sequencing, Laboratory of Personalized Genomic Medicine


DIGITAL PATHOLOGY AND IMMUNE CHECKPOINT THERAPY

Tissue-Based Assessment of PD-L1 and Other Tumor Microenvironmental Factors in Melanoma Specimens

Janis M. Taube, M.D., MSc, Director, Dermatopathology; Assistant Professor, Dermatology and Pathology, Johns Hopkins

Tissue-Based Analyses to Guide Immunotherapy for Lymphoma

Scott Rodig, M.D., Ph.D., Hematopathologist, Pathology, Brigham and Women’s Hospital

Immune Profiling of Lung Cancer Tissue Specimens

Ignasio I. Wistuba, M.D., Chair, Translational Molecular Pathology, Division of Pathology/Lab Medicine; Anderson Clinical Faculty Chair, Cancer Treatment and Research, The University of Texas MD Anderson Cancer Center

Beyond PD-L1: Other Potential Companion Diagnostic Tests for Immune Checkpoint Therapy

David L. Rimm, M.D., Ph.D., Professor, Pathology, Yale University


TARGETED PANELS VS. EXOME SEQUENCING: BALANCING COST WITH RESULTS

The Utility of Exome Sequencing in Providing Deep Coverage of Disease-Relevant Targets

Avni B. Santani, Ph.D., Assistant Professor, Clinical Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia

Diagnostic Gene Panels in the Exome Era – Using Exome Sequencing as a Universal Assay to Streamline Assay Development and Laboratory Operations

Birgit H. Funke, Ph.D., FACMG, Associate Professor, Pathology, MGH/Harvard Medical School; Director, Clinical Research and Development, Laboratory for Molecular Medicine - Partners HealthCare


WHY TARGETED THERAPIES FAIL

Precision Medicine and Cancer Drug Discovery

Atul J. Butte, M.D., Ph.D., Director, Institute for Computational Health Sciences; Professor, Pediatrics, University of California, San Francisco

Characterization of Driver Alterations in Tissue and Liquid Biopsies

Victor Velculescu, M.D., Ph.D., Professor, Oncology; Co-Director, Cancer Biology, Johns Hopkins Sidney Kimmel Cancer Center; Co-Founder, Personal Genome Diagnostics

Enterprise-Wide Clinical Sequencing to Match Patients to Personalized Cancer Therapies

Michael F. Berger, Ph.D., Associate Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center


HOT TOPICS AND CONTROVERSIES IN CANCER SEQUENCING

Novel Clinical Applications of Cancer Genomics

Luis A. Diaz, M.D., Associate Professor, Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

What is a Cancer Mutation: The Difficulties of Benchmarking Somatic Genetic Variants in Cancer

Joshua M. Stuart, Ph.D., Baskin Engineering Endowed Chair & Professor, Biomolecular Engineering; Associate Director, Center for Biomolecular Science and Engineering, University of California, Santa Cruz

Noninvasive Monitoring of Lymphoma by Sequencing of Circulating Tumor DNA

Ash A. Alizadeh, Ph.D., Principal Investigator, Assistant Professor, Medicine, Divisions of Oncology & Hematology; Attending Physician, Lymphoma Oncology Clinic, Stanford Cancer Center, Stanford University

Darwinian Evolution: The Elephant in the Cancer Genome Room

German Pihan, M.D., Staff Pathologist and Director, Diagnostic Hematopathology Service, Department of Pathology, Beth Israel Deaconess Medical Center

Who Should Regulate Cancer NGS Tests: FDA, CMS/CLIA, or Both?

Roger D. Klein, M.D., J.D., Chair, Professional Relations Committee, Association for Molecular Pathology (AMP); Medical Director, Molecular Oncology, Cleveland Clinic

Premier Sponsors:  

Bina Technologies

Coyote

Elsevier   

Jackson Laboratory - small logo 

 NanoString2   

 Precision for Medicine 

SeraCare(2)

Silicon Biosystems

Thomson Reuters-Large